Alzheimer’s remains one of the biggest puzzles in the medical world. It’s a devastating disease that impacts millions of people across the globe, but there are no treatments that can halt or reverse it.
M3 Biotechnology, a Seattle-based biotech startup, is hoping it has the answer to that puzzle. The company just launched its first clinical trial to test a drug it says could halt or reverse the nerve damage that causes Alzheimer’s. It has also raised $15.2 million in new funding to support that work, GeekWire has learned.